ARSK

Across TCGA pan-cancer cohorts, ARSK mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ARSK data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ARSK mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARSK expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

PDAC, CCRCC, and GBM are the cancer types where ARSK mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.123	0.861	.024	8	view →
CCRCC	OS	Median	All	0.966	0.369	.014	3	view →
GBM	DFS	Quartile	All	0.492	0.295	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ARSK–PDAC (DFS)

Open the PDAC breakdown →